Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CASP1 | P29466 | 2/20 | 0.48 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.43 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.43 |
| ▸ | FKBP1A | P62942 | 4/20 | 0.42 |
| ▸ | SCN9A | Q15858 | 4/20 | 0.42 |
| ▸ | CTSL | P07711 | 1/20 | 0.41 |
| ▸ | XIAP | P98170 | 4/20 | 0.41 |
| ▸ | CASP3 | P42574 | 1/20 | 0.40 |
| ▸ | NPY1R | P25929 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9973466 | 0.93 | CASP1 (0.48) | CASP1KMT2AL3MBTL1FKBP1ASCN9A | |
| SCHEMBL25873179 | 0.89 | CASP1 (0.56) | CASP1KMT2AL3MBTL1FKBP1ACTSL | |
| SCHEMBL9973474 | 0.89 | CASP1 (0.54) | CASP1KMT2AL3MBTL1FKBP1ACTSL | |
| SCHEMBL31384817 | 0.86 | CASP1 (0.49) | CASP1KMT2AL3MBTL1FKBP1ACTSL | |
| SCHEMBL9973467 | 0.86 | CASP1 (0.49) | CASP1KMT2AL3MBTL1FKBP1ACTSL | |
| SCHEMBL9973469 | 0.86 | CASP1 (0.49) | CASP1KMT2AL3MBTL1FKBP1ACTSL | |
| SCHEMBL1299624 | 0.86 | CASP1 (0.47) | CASP1KMT2AL3MBTL1FKBP1ACTSL | |
| SCHEMBL19199495 | 0.86 | CASP1 (0.47) | CASP1KMT2AL3MBTL1FKBP1ACTSL | |
| SCHEMBL19194321 | 0.86 | CASP1 (0.47) | CASP1KMT2AL3MBTL1FKBP1ACTSL | |
| SCHEMBL1299623 | 0.86 | CASP1 (0.47) | CASP1KMT2AL3MBTL1FKBP1ACTSL |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8202902-B2 | Bivalent SMAC mimetics and the uses thereof | THE REGENTS OF THE UNIVERSITY OF MICHIGAN (US) | 2012-06-19 | — | — | US | disclosed |
| US-7960372-B2 | Inhibitors of apoptosis proteins; antiproliferative agents; kits | THE REGENTS OF THE UNIVERSITY OF MICHIGAN (US) | 2011-06-14 | — | — | US | disclosed |
| US-20090123480-A1 | BIVALENT SMAC MIMETICS AND THE USES THEREOF | THE REGENTS OF THE UNIVERSITY OF MICHIGAN (US) | 2009-05-14 | — | — | US | disclosed |
| US-20080089896-A1 | Bivalent SMAC mimetics and the uses thereof | REGENTS OF THE UNIVERSITY OF MICHIGAN (US) | 2008-04-17 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080089896-A1 | Bivalent SMAC mimetics and the uses thereof | BID, BAD, BIRC2 | CASP1 189/4885KMT2A 1411/4885L3MBTL1 788/4885 |
| US-20090123480-A1 | BIVALENT SMAC MIMETICS AND THE USES THEREOF | BID, BAD, BIRC2 | CASP1 189/4885KMT2A 1411/4885L3MBTL1 788/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.